Stable Complexes Involving Acetylcholinesterase and Amyloid-β Peptide Change the Biochemical Properties of the Enzyme and Increase the Neurotoxicity of Alzheimer’s Fibrils

Brain acetylcholinesterase (AChE) forms stable complexes with amyloid-β peptide (Aβ) during its assembly into filaments, in agreement with its colocalization with the Aβ deposits of Alzheimer’s brain. The association of the enzyme with nascent Aβ aggregates occurs as early as after 30 min of incubation. Analysis of the catalytic activity of the AChE incorporated into these complexes shows an anomalous behavior reminiscent of the AChE associated with senile plaques, which includes a resistance to low pH, high substrate concentrations, and lower sensitivity to AChE inhibitors. Furthermore, the toxicity of the AChE–amyloid complexes is higher than that of the Aβ aggregates alone. Thus, in addition to its possible role as a heterogeneous nucleator during amyloid formation, AChE, by forming such stable complexes, may increase the neurotoxicity of Aβ fibrils and thus may determine the selective neuronal loss observed in Alzheimer’s brain.

[1]  C. Geula,et al.  Anatomy of cholinesterase inhibition in Alzheimer's disease: Effect of physostigmine and tetrahydroaminoacridine on plaques and tangles , 1987, Annals of neurology.

[2]  B. P. Doctor,et al.  A monoclonal antibody against acetylcholinesterase inhibits the formation of amyloid fibrils induced by the enzyme. , 1997, Biochemical and biophysical research communications.

[3]  Claudia Linker,et al.  Acetylcholinesterase Accelerates Assembly of Amyloid-β-Peptides into Alzheimer's Fibrils: Possible Role of the Peripheral Site of the Enzyme , 1996, Neuron.

[4]  E. Mufson,et al.  Ultrastructural localization of acetylcholinesterase in neurofibrillary tangles, neuropil threads and senile plaques in aged and Alzheimer's brain , 1992, Brain Research.

[5]  F. Grosveld,et al.  Frameshift mutants of beta amyloid precursor protein and ubiquitin-B in Alzheimer's and Down patients. , 1998, Science.

[6]  K. Courtney,et al.  A new and rapid colorimetric determination of acetylcholinesterase activity. , 1961, Biochemical pharmacology.

[7]  D. Selkoe,et al.  Alzheimer's Disease--Genotypes, Phenotype, and Treatments , 1997, Science.

[8]  F. Vallette,et al.  Molecular and cellular biology of cholinesterases , 1993, Progress in Neurobiology.

[9]  N. Inestrosa,et al.  Acetylcholinesterase, a senile plaque component, affects the fibrillogenesis of amyloid-β-peptides , 1995, Neuroscience Letters.

[10]  Y. Mimori,et al.  Abnormalities of acetylcholinesterase in Alzheimer's disease with special reference to effect of acetylcholinesterase inhibitor , 1997, Behavioural Brain Research.

[11]  M Nirenberg,et al.  Synapse turnover: the formation and termination of transient synapses. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[12]  N. Inestrosa,et al.  Acetylcholinesterase is a senile plaque component that promotes assembly of amyloid beta-peptide into Alzheimer's filaments. , 1996, Molecular psychiatry.

[13]  M. Mesulam,et al.  Protease inhibitors and indoleamines selectively inhibit cholinesterases in the histopathologic structures of Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[14]  M. Karnovsky,et al.  A "DIRECT-COLORING" THIOCHOLINE METHOD FOR CHOLINESTERASES , 1964, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[15]  C. Geula,et al.  Competitive substrate inhibition in the histochemistry of cholinesterase activity in Alzheimer's disease , 1990, Neuroscience Letters.

[16]  S. Snyder,et al.  Gamma-aminobutyric acid (GABA) receptor binding in mammalian retina , 1976, Brain Research.

[17]  Y. Ashani,et al.  Characterization of Monoclonal Antibodies that Inhibit the Catalytic Activity of Acetylcholinesterases , 1995, Journal of neurochemistry.

[18]  P. Lansbury,et al.  The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. , 1993, Biochemistry.

[19]  R. Silveira,et al.  Fasciculin, a powerful anticholinesterase polypeptide from Dendroaspis angusticeps venom , 1983, Neurochemistry International.

[20]  A. W. Peck,et al.  Hydrolysis of suxamethonium by different types of plasma , 1969, British journal of pharmacology.

[21]  Peter Davies,et al.  Identification of normal and pathological aging in prospectively studied nondemented elderly humans , 1992, Neurobiology of Aging.

[22]  L. Greene,et al.  Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. , 1976, Proceedings of the National Academy of Sciences of the United States of America.

[23]  P. Lansbury,et al.  Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[24]  L. Thal,et al.  Properties of dopamine agonist and antagonist binding sites in mammalian retina , 1980, Brain Research.

[25]  U. Bachrach,et al.  ORNITHINE AND GLUTAMIC ACID DECARBOXYLASE ACTIVITIES IN THE DEVELOPING CHICK RETINA , 1976, Journal of neurochemistry.

[26]  C. Geula,et al.  Electron microscopic localization of cholinesterase activity in Alzheimer brain tissue , 1991, Brain Research.

[27]  C. Geula,et al.  Special properties of cholinesterases in the cerebral cortex of Alzheimer's disease , 1989, Brain Research.

[28]  G. Getz,et al.  Effect of Apolipoprotein E on Neurite Outgrowth and β‐Amyloid‐Induced Toxicity in Developing Rat Primary Hippocampal Cultures , 1997, Journal of neurochemistry.

[29]  C. Soto,et al.  Structural Determinants of the Alzheimer's Amyloid β‐Peptide , 1994 .

[30]  M. Mattson,et al.  beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[31]  M. Pras,et al.  Apolipoprotein E Carboxyl-terminal Fragments Are Complexed to Amyloids A and L , 1995, The Journal of Biological Chemistry.

[32]  C. Wernstedt,et al.  Characterization of stable complexes involving apolipoprotein E and the amyloid β peptide in Alzheimer's disease brain , 1995, Neuron.

[33]  N. Inestrosa,et al.  Cellular localization of the molecular forms of acetylcholinesterase in rat pheochromocytoma PC12 cells treated with nerve growth factor , 1981, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[34]  N. Inestrosa,et al.  Distribution and anchoring of molecular forms of acetylcholinesterase. , 1989, Trends in pharmacological sciences.

[35]  B. Yankner,et al.  Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[36]  M. Nirenberg,et al.  Localization of Acetylcholine Receptors during Synaptogenesis in Retina (a-bungarotoxin/neuron Development/cultured Neurons) , 2022 .

[37]  D. Selkoe,et al.  Immunochemical identification of the serine protease inhibitor α 1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease , 1988, Cell.

[38]  D. Nochlin,et al.  The presence of heparan sulfate proteoglycans in the neuritic plaques and congophilic angiopathy in Alzheimer's disease. , 1988, The American journal of pathology.

[39]  E. Rojas,et al.  Giant multilevel cation channels formed by Alzheimer disease amyloid beta-protein [A beta P-(1-40)] in bilayer membranes. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[40]  P. Layer Non-classical actions of cholinesterases: Role in cellular differentiation, tumorigenesis and Alzheimer's disease , 1996, Neurochemistry International.

[41]  M. Nirenberg,et al.  Muscarinic acetylcholine receptors of the developing retina. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[42]  P. Taylor,et al.  The cholinesterases. , 1991, The Journal of biological chemistry.

[43]  M. Mattson,et al.  A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[44]  H. Levine,et al.  Thioflavine T interaction with synthetic Alzheimer's disease β‐amyloid peptides: Detection of amyloid aggregation in solution , 1993, Protein science : a publication of the Protein Society.

[45]  D. Kukuruga,et al.  Purification, ultrastructure, and chemical analysis of Alzheimer disease amyloid plaque core protein. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[46]  P. May,et al.  Clusterin (Apo J) Protects Against In Vitro Amyloid‐β(1–40) Neurotoxicity , 1996 .

[47]  J. Hofrichter,et al.  Kinetics of sickle hemoglobin polymerization. II. A double nucleation mechanism. , 1985, Journal of molecular biology.

[48]  N. Inestrosa,et al.  Acetylcholinesterase from bovine caudate nucleus is attached to membranes by a novel subunit distinct from those of acetylcholinesterases in other tissues. , 1987, The Journal of biological chemistry.

[49]  B. Solomon,et al.  Disaggregation of Alzheimer β-amyloid by site-directed mAb , 1997 .

[50]  N. Inestrosa,et al.  Acetylcholinesterase promotes the aggregation of amyloid-beta-peptide fragments by forming a complex with the growing fibrils. , 1997, Journal of molecular biology.

[51]  P. Cras,et al.  Senile plaque neurites in Alzheimer disease accumulate amyloid precursor protein. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[52]  J. Hofrichter,et al.  Kinetics of sickle hemoglobin polymerization. I. Studies using temperature-jump and laser photolysis techniques. , 1985, Journal of molecular biology.

[53]  Bruce A. Yankner,et al.  Methodological variables in the assessment of beta amyloid neurotoxicity , 1992, Neurobiology of Aging.

[54]  R. Silveira,et al.  Rat striatal acetylcholinesterase inhibition by Fasciculin (a polypeptide from green mamba snake venom) , 1987, Neuroscience Letters.

[55]  C. Geula,et al.  Protease Inhibitors and Indolamines Selectively Inhibit Cholinesterases in the Histopathologic Structures of Alzheimer's Disease a , 1993, Annals of the New York Academy of Sciences.

[56]  R. Kalaria,et al.  Acetylcholinesterase and its association with heparan sulphate proteoglycans in cortical amyloid deposits of Alzheimer's disease , 1992, Neuroscience.

[57]  E. Otomo,et al.  Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease , 1991, Brain Research.

[58]  K. Iqbal,et al.  Alzheimer's disease : biology, diagnosis, and therapeutics , 1996 .

[59]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[60]  E. Karlsson,et al.  Fasciculins, anticholinesterase toxins from the venom of the green mamba Dendroaspis angusticeps. , 1984, Journal de physiologie.

[61]  D. Selkoe,et al.  Amyloid β-Protein and the Genetics of Alzheimer's Disease* , 1996, The Journal of Biological Chemistry.

[62]  J. Sheffield,et al.  Electron microscopic analysis of aggregation of embryonic cells: the structure and differentiation of aggregates of neural retina cells. , 1970, Developmental biology.

[63]  R. Wetzel,et al.  Aggregation state and neurotoxic properties of Alzheimer beta-amyloid peptide. , 1995, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.

[64]  C. Geula,et al.  Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia , 1994, Annals of neurology.

[65]  P. Lansbury,et al.  Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. , 1997, Annual review of biochemistry.

[66]  C. Masters,et al.  Amyloid plaque core protein in Alzheimer disease and Down syndrome. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[67]  P. Taylor,et al.  Role of the peripheral anionic site on acetylcholinesterase: inhibition by substrates and coumarin derivatives. , 1991, Molecular pharmacology.

[68]  Carl W. Cotman,et al.  Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[69]  N. Inestrosa,et al.  Toxic effects of acetylcholinesterase on neuronal and glial-like cells in vitro , 1998, Molecular Psychiatry.

[70]  B. Yankner,et al.  β-Amyloid fibrils induce tau phosphorylation and loss of microtubule binding , 1995, Neuron.

[71]  L. Villa-komaroff,et al.  Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. , 1989, Science.

[72]  C. Glabe,et al.  Surfactant properties of Alzheimer's A beta peptides and the mechanism of amyloid aggregation. , 1994, The Journal of biological chemistry.

[73]  J. Pettegrew,et al.  Two simple methods for quantifying low-affinity dye-substrate binding. , 1989, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[74]  Steven A. Johnson,et al.  Clusterin (apoJ) Alters the Aggregation of Amyloid β-Peptide (Aβ1-42) and Forms Slowly Sedimenting Aβ Complexes That Cause Oxidative Stress , 1995, Experimental Neurology.

[75]  B. Yankner Mechanisms of Neuronal Degeneration in Alzheimer's Disease , 1996, Neuron.

[76]  T. Mosmann Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[77]  S. Nakano,et al.  Subcellular distribution of acetylcholinesterase in Alzheimer's disease: abnormal localization and solubilization. , 1990, Journal of neural transmission. Supplementum.

[78]  K. Gulya,et al.  The cholinergic system in Alzheimer's disease , 1997, Progress in Neurobiology.

[79]  M. Nirenberg,et al.  Synapse and acetylcholine receptor synthesis by neurons dissociated from retina. , 1976, Proceedings of the National Academy of Sciences of the United States of America.

[80]  H. Schägger,et al.  Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. , 1987, Analytical biochemistry.

[81]  M A Markwell,et al.  A new solid-state reagent to iodinate proteins. I. Conditions for the efficient labeling of antiserum. , 1982, Analytical biochemistry.

[82]  D. Mann,et al.  The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's syndrome , 1989, Journal of the Neurological Sciences.

[83]  Shen Zx Acetylcholinesterase provides deeper insights into Alzheimer's disease , 1994 .

[84]  K. Higuchi,et al.  Kinetic analysis of amyloid fibril polymerization in vitro. , 1991, Laboratory investigation; a journal of technical methods and pathology.

[85]  Claudia H. Kawas,et al.  The epidemiology of dementia and Alzheimer disease. , 1994 .

[86]  F. G. Mello,et al.  Adenosine‐Elicited Accumulation of Adenosine 3′, 5′‐Cyclic Monophosphate in the Chick Embryo Retina , 1982 .

[87]  W. Surewicz,et al.  Mechanisms of neurotoxicity associated with amyloid beta deposition and the role of free radicals in the pathogenesis of Alzheimer's disease: a critical appraisal. , 1997, Chemical research in toxicology.